Potential methods to prevent interstitial fibrosis in renal disease

Expert Opinion on Investigational Drugs

Volumn 10, Issue 11, 2001, Pages 1989-2001

  Strutz, F ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

EGF; FGF 2; Fibrosis; Pirfenidone; Progression; Relaxin; TGF 1

Indexed keywords

6,7 DIMETHYL 2 PHENYLQUINOXALINE; ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; COLCHICINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GLUCOSE; IMATINIB; INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MITHRAMYCIN; MITOMYCIN C; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUTRALIZING ANTIBODY; OSTEOGENIC PROTEIN 1; PENTIFYLLINE; PENTOXIFYLLINE; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR BETA1; TRAPIDIL; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; UNINDEXED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ATROPHY; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DRUG POTENCY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE; MOUSE; NEPHRITIS; NONHUMAN; REVIEW; RISK FACTOR; RISK MANAGEMENT; TREATMENT OUTCOME;

ANIMALS; EXTRACELLULAR MATRIX; FIBROBLASTS; FIBROSIS; HUMANS; INFLAMMATION; KIDNEY DISEASES;

EID: 0035169893     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.10.11.1989     Document Type: Review

References (152)

1. Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy
2. Nephropathy in patients with Type 2 diabetes mellitus
3. The effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease
4. The renal tubule in the progression of chronic renal failure
5. On the progression of chronic renal disease
6. Sustained expression of TGF-β1 underlies development of progressive kidney fibrosis
7. On the pathogenesis of chronic renal failure in primary glomerulopathies
8. The long-term prognosis of the primary glomerulonephritides
9. Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters
10. The influence of glomerular and interstitial factors on the serum creatinine concentration and serum creatinine concentration in renal amyloidosis
11. Interstitial fibrosis of the renal cortex in minimal change lesion and its correlation with renal function
12. Significance of tubulointerstitial changes in diabetic renal disease
13. Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats
14. Renal Fibrosis: Prevention of progression - How far are we?
15. Reversal of lesions of diabetic nephropathy after pancreas transplantation
16. Anti-inflammatory actions of steroids: Molecular mechanisms
17. Neutralizing inflammatory cytokines in nephritis
18. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus
19. Retinopathy and nephropathy in patients with Type 1 diabetes four years after a trial of intensive therapy
20. Diabetic nephropathy: From micro- to macroalbuminuria
21. Progression of diabetic nephropathy in normotensive Type 1 diabetic patients
22. Renoprotection: One or many therapies?
23. Renal renin-angiotensin system in diabetes: Functional, immunohistochemical, and molecular biological correlations
24. Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat
25. The beneficial effect of angiotensin converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria
26. Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts
27. Enalapril reduces Type IV collagen synthesis and expansion of the interstitium in the obstructed kidney
28. Irreversible tubulointerstitial damage associated with chronic aminonucleoside nephrosis. Amelioration by angiotensin I converting enzyme inhibition
29. Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease: A systematic overview of randomized placebo-controlled trials
30. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency
31. Angiotensin-converting enzyme inhibitors and kidney protection: The AIPRI trial
32. Differences in renal outcomes with ACE inhibitors in Type 1 and Type 2 diabetic patients: Possible explanations
33. Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy
34. Effects of angiotensin inhibitors on renal injury and angiotensin receptor expression in early hypertensive nephrosclerosis
35. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure
36. Blockade of the renin-angiotensin and endothelin systems on progressive renal injury
37. Targeting TGF-beta overexpression in renal disease: Maximizing the antifibrotic action of angiotensin II blockade
38. Mechanisms underlying renoprotection during renin-angiotensin system blockade
39. Angiotensin II receptor antagonists versus angiotensin converting enzyme inhibitors: Effects on renal function
40. Angiotensin receptor blockers in chronic renal disease: The promise of a bright clinical future
41. Angiotensin converting enzyme inhibitors and calcium antagonists alone or combined: Does the progression of diabetic renal disease differ?
42. Renoprotective effects of antihypertensive drugs
43. Calcium antagonists and the progression of chronic renal failure
44. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: A randomized controlled trial
45. Glomerular hypertrophy aggravates epithelial cell injury in nephrotic rats
46. Low-protein diet attenuates increased gene expression of platelet-derived growth factor and transforming growth factor-β in experimental glomerular sclerosis
47. Low protein diet blunts the rise in glomerular gene expression in focal glomerulosclerosis
48. Development of injury in a rat model of chronic renal allograft rejection: Effect of dietary protein restriction
49. Nutrition and outcome on renal replacement therapy of patients with chronic renal failure treated by a supplemented very low protein diet
50. Blockade of leucocyte function-associated antigen (LFA-1) in a murine model of lung inflammation
51. Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist
52. Antibodies to intercellular adhesion molecule 1/lymphocyte function- associated antigen 1 prevent crescent formation in rat autoimmune glomerulonephritis
53. Inhibition of intercellular adhesion molecule-1 with antisense deoxynucleotides prolongs renal isograft survival in the rat
54. Effect of antibody against integrin alpha4 on bleomycin-induced pulmonary fibrosis in mice
55. Global gene expression analysis reveals a role for the alphasub1 integrin in renal pathogenesis
56. Treatment with an antibody to VLA-1 integrin reduces tubulointerstitial scarring in a model of crescentic glomerulonephritis
57. Contributions of angiotensin II and tumor necrosis factor-a to the development of renal fibrosis
58. Role of TNFR1 and TNFR2 receptors in tubulointerstitial fibrosis of obstructive nephropathy
59. Tumour necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis
60. An interleukin-1 receptor antagonist decreases fibrosis induced by dimethylnitrosamine in rat liver
61. IL-1 receptor antagonist ameliorates experimental anti-GBM antibody associated glomerulonephritis
62. Targeting signal transduction for disease therapy
63. Transforming growth factor (TGF)-β1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2)
64. PDGF receptor kinase blocker AG1295 attenuates interstitial fibrosis in rat kidney after unilateral obstruction
65. Retinoic acid reduces glomerular injury in a rat model of glomerular damage
66. Novel approach to specific growth factor inhibition in vivo: Antagonism of platelet-derived growth factor in glomerulonephritis by aptamers
67. Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis
68. Platelet-derived growth factor: A new clinical target on the horizon
69. The biology and treatment of chronic myelogenous leukemia
70. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis
71. Trapidil inhibits human mesangial cell proliferation: Effect on PDGF beta-receptor binding and expression
72. Basic fibroblast growth factor (FGF-2) expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation
73. Effects of pentoxifylline, pentifylline and gamma-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts
74. Pentoxifylline reduces in vitro renal myofibroblast proliferation and collagen secretion
75. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis
76. Striking regression of subcutaneous fibrosis induced by high doses of gamma rays using a combination of pentoxifylline and alpha-tocopherol: An experimental study
77. Influence of prophylactic use of pentoxifylline on postoperative organ function in elderly cardiac surgery patients
78. Use of pentoxifylline in membranous nephropathy
79. Pentoxifylline blocks hepatic stellate cell activation independently of phosphodiesterase inhibitory activity
80. Mycophenolate mofetil prevents the progressive renal failure induced by 5/6 renal ablation in rats
81. Attenuation of murine lupus nephritis by mycophenolate mofetil
82. Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals
83. Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney
84. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney
85. Abnormal growth and clonal proliferation of fibroblasts derived from kidneys with interstitial fibrosis
86. In vitro effects of simvastatin on tubulointerstitial cells in a human model of cyclosporin nephrotoxicity
87. Recent advances in statins and the kidney
88. Conditional abatement of tissue fibrosis using nucleoside analogs to selectively corrupt DNA replication in transgenic fibroblasts
89. Gene transfer targeting interstitial fibroblasts by the artificial viral envelope-type haemagglutinating virus of Japan liposome method
90. Two different cis-acting regulatory regions direct cell-specific transcription of the collagen α1(I) gene in hepatic stellate cells and in skin and tendon fibroblasts
91. Mithramycin selectively inhibits collagen-α1(I) gene expression in human fibroblast
92. Pentoxifylline, Pentifylline, and interferons decrease Type I and III procollagen mRNA levels in dermal fibroblasts: Evidence for mediation by nuclear factor 1 down-regulation
93. γ interferon is the lymphokine and β interferon the monokine responsible for inhibition of fibroblast collagen production and late but not early fibroblast proliferation
94. Interferon-γ reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-β in normal human fibroblasts
95. α-smooth muscle actin is expressed in a subpopulation of cultured and cloned fibroblasts and is modulated by γ-interferon
96. Treatment of systemic sclerosis with γ-interferon
97. Interferon-gamma inhibits experimental renal fibrosis
98. IFN-γ mediates crescent formation and cell-mediated immune injury in murine glomerulonephritis
99. TGF-β in kidney fibrosis: A target for gene therapy
100. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1
101. Natural inhibitor of transforming growth factor-β protects against scarring in experimental kidney disease
102. Tandem antifibrotic actions of L-arginine supplementation and low protein diet during the repair phase of experimental glomerulonephritis
103. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: Possible role of TGF-beta
104. The tubulointerstitium in progressive diabetic kidney disease: More than an aftermath of glomerular injury?
105. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice
106. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice
107. Effect of antibody to transforming growth factor β on bleomycin induced accumulation of lung collagen in mice
108. Neutralization of transforming growth factor-beta 1 in a mouse model of immune-induced lung fibrosis
109. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters
110. Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy
111. The integrin alpha v beta 6 binds and activates latent TGF beta 1: A mechanism for regulating pulmonary inflammation and fibrosis
112. Integrin-mediated activation of transforming growth factor-beta(1) in pulmonary fibrosis
113. Targeted disruption of the mouse transforming growth factor beta 1 results in multifocal inflammatory disease
114. TGF-beta and regulation of interstitial nephritis
115. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters
116. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label Phase II study
117. A Phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel antifibrosing agent, in myelofibrosis with myeloid metaplasia
118. Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy
119. Pirfenidone improves renal function and fibrosis in the post-obstructed kidney
120. Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats
121. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level
122. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation
123. Colchicine in the treatment of cirrhosis of the liver
124. Effect of colchicine for primary biliary cirrhosis
125. Combination therapy with ursodeoxycholic acid and colchicine for primary biliary cirrhosis
126. Colchicine does not ameliorate bleomycin-induced pulmonary injury in hamsters
127. Effect of colchicine on chronic ciclosporin nephrotoxicity in Sprague-Dawley rats
128. BMP 7 is required for nephrogenesis, eye development, and skeletal patterning
129. BMP7 null mutation in mice: Developmental defects in skeleton, kidney, and eye
130. Expression of bone morphogenetic protein-7 mRNA in normal and ischaemic adult rat kidney
131. Osteogenic protein-1 (OP-1), an inducer of tubulogenesis in kidney development, mediates anti-fibrogenic effects in vitro
132. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction
133. Matrix metalloproteinases: Biologic activity and clinical implications
134. Extracellular matrix 6: Role of matrix metalloproteinases in tumor invasion and metastasis
135. Tissue inhibitors of metalloproteinases: Evolution, structure and function
136. Interstitial fibrosis in mice with overload proteinuria: Deficiency of TIMP-1 is not protective
137. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria
138. Inhibition of the matrix metalloproteinase system in a rat model of chronic cyclosporin nephropathy
139. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition
140. Regression of sclerosis in aging by an angiotensin inhibition-induced decrease in PAI-1
141. Plasminogen activator inhibitor Type 1 is a potential target in renal fibrogenesis
142. Endogenous hepatocyte growth factor ameliorates chronic renal injury by activating matrix degradation pathways
143. Hepatocyte growth factor in renal failure: Promise and reality
144. Relaxin: More than just a hormone of pregnancy
145. Relaxin is a potent renal vasodilator in conscious rats
146. Relaxin is essential for renal vasodilation during pregnancy in conscious rats
147. Human relaxin decreases collagen accumulation in vivo in two rodent models of fibrosis
148. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo
149. Recombinant human relaxin in the treatment of scleroderma. A randomized, double blind, placebo-controlled trial
150. Relaxin as an antifibrotic agent - Properties, functions and mechanisms
151. Relaxin decreases renal interstitial fibrosis and slows progression of renal disease
152. Neointimal and tubulointerstitial infiltration by recipient mesenchymal cells in chronic renal-allograft rejection